AMPE Stock Overview
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Ampio Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.25 |
52 Week High | US$8.30 |
52 Week Low | US$0.14 |
Beta | 1.95 |
1 Month Change | -72.72% |
3 Month Change | -87.13% |
1 Year Change | -93.66% |
3 Year Change | -99.96% |
5 Year Change | -99.85% |
Change since IPO | -99.96% |
Recent News & Updates
Shareholder Returns
AMPE | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -12.2% | 0.3% | 2.2% |
1Y | -93.7% | 9.8% | 22.8% |
Return vs Industry: AMPE underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: AMPE underperformed the US Market which returned 22.8% over the past year.
Price Volatility
AMPE volatility | |
---|---|
AMPE Average Weekly Movement | 42.8% |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMPE's share price has been volatile over the past 3 months.
Volatility Over Time: AMPE's weekly volatility has increased from 38% to 43% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 6 | Mike Martino | ampiopharma.com |
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.
Ampio Pharmaceuticals, Inc. Fundamentals Summary
AMPE fundamental statistics | |
---|---|
Market cap | US$431.44k |
Earnings (TTM) | -US$8.63m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs AMPE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AMPE income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$8.63m |
Earnings | -US$8.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -7.60 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 5.3% |
How did AMPE perform over the long term?
See historical performance and comparison